The U.S. Food and Drug Administration has agreed to allow Myeliviz, an imaging agent of myelin — the protective layer that covers nerve fibers and is damaged in multiple sclerosis (MS) — to be evaluated in a clinical trial with healthy volunteers.
Myeliviz, created by Case Western Reserve University researchers, has the potential to be used in diagnosing MS, as well as other myelin-associated diseases, and in monitoring disease progression.
“Myelin has never been directly imaged before. Our technique is the first to do so, and we are hopeful that this will provide earlier and more accurate diagnosis of MS,” Yanming Wang, PhD, Myeliviz’s co-inventor and a professor of radiology at the Case Western Reserve School of Medicine, said in a press release.
https://multiplesclerosisnewstoday.c...clinical-trial
Myeliviz, created by Case Western Reserve University researchers, has the potential to be used in diagnosing MS, as well as other myelin-associated diseases, and in monitoring disease progression.
“Myelin has never been directly imaged before. Our technique is the first to do so, and we are hopeful that this will provide earlier and more accurate diagnosis of MS,” Yanming Wang, PhD, Myeliviz’s co-inventor and a professor of radiology at the Case Western Reserve School of Medicine, said in a press release.
https://multiplesclerosisnewstoday.c...clinical-trial
Comment